Genetic counseling, testing and management of prostate adenocarcinoma patients: recommendations from a consensus of experts from the National Institute of Neoplastic Diseases of Peru

Abstract

The objective was to provide tools for genetic profiling and treatment of patients with prostate adenocarcinoma. The Consensus was made up of oncologists and geneticists from the National Institute of Neoplastic Diseases of Peru and followed the guidelines of the “Consensus Conference on Standard Operating Procedures of the European Society of Medical Oncology”. The GRADE methodology was applied to assess the evidence and make recommendations. The clinical practice guidelines were graded following the "AGREE II". All patients with prostate adenocarcinoma and risk factors should be ordered genetic testing and counseling; Testing should include BRCA1/2, ATM, CHECK2 PALB2, MLH1, MSH2/6, and PMS2. Additional genes may be requested based on the clinical condition. In patients with metastatic castration-resistant or regional prostate cancer, somatic testing may be considered. The result of the test can guide the treatment. In conclusion, there are many unmet needs in the approach and management of prostate cancer. Cancer genetic risk assessment and genetic counseling involves the identification and counseling of individuals at risk for hereditary cancer. Genetic counseling and testing are expected to be included in daily clinical practice.